The efficacy and safety of direct oral anticoagulants compared with low‐molecular‐weight heparin for venous thromboembolism prophylaxis after surgical resection of primary lower extremity bone or soft‐tissue sarcoma
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27519 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Christa L LiBrizzi und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Division of Orthopaedic Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Venous Thromboembolism, Pulmonary Embolism, Soft Tissue Neoplasms, Sarcoma. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Themen: Thromboseprophylaxe
Abstract (Originalsprache)
Introduction
The incidence of postoperative venous thromboembolism (VTE) and wound complications is greater after sarcoma resection. We sought to identify differences in postoperative VTE and bleeding complications with direct oral anticoagulants (DOACs) versus low‐molecular‐weight heparin (LMWH) following resection of lower extremity primary bone or soft tissue sarcoma.
Methods
We retrospectively identified 2083 patients from the PearlDiver database who underwent resection of primary bone or soft tissue sarcoma of the lower extremity from January 2010 to October 2021 and prescribed LMWH or DOAC within 90‐days postoperatively. The primary outcomes were comparison of postoperative incidence and odds of deep venous thrombosis (DVT), pulmonary embolism (PE), and bleeding complications within 90‐days following resection.
Results
Patients prescribed DOACs had a greater odds of DVT (odds ratio [OR]: 1.60; 95% confidence interval [CI]: 1.06–2.41; p = 0.024) and PE (OR: 3.38; 95% CI: 1.96–5.86; p < 0.001) within 90‐days following resection of bone sarcoma when compared with the LMWH cohort. Patients undergoing resection of soft tissue sarcomas also had greater odds DVT (OR: 1.65; 95% CI: 1.09–2.49; p = 0.016) and PE (OR: 2.62; 95% CI: 1.52–4.54; p < 0.001) in the DOAC cohort. There was no difference in the odds of bleeding complications.
Conclusion
This study demonstrated an increased incidence and odds of VTE, but not bleeding complications, when using DOACs versus LMWH after primary bone or soft tissue sarcoma resection. Level of Evidence Level III.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Orthopaedic Surgery, Division of Orthopaedic Oncology, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
- Department of Orthopaedic Surgery, George Washington University School of Medicine and Health Sciences, Washington, District of Columbia, USA.
- Division of Orthopaedic Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Zitieren
APA
LiBrizzi, C. L., Agarwal, A. R., Chiu, A. K., Morris, C. D., Thakkar, S. C., & Levin, A. S. (2024). The efficacy and safety of direct oral anticoagulants compared with low‐molecular‐weight heparin for venous thromboembolism prophylaxis after surgical resection of primary lower extremity bone or soft‐tissue sarcoma. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27519
Vancouver
LiBrizzi CL, Agarwal AR, Chiu AK, Morris CD, Thakkar SC, Levin AS. The efficacy and safety of direct oral anticoagulants compared with low‐molecular‐weight heparin for venous thromboembolism prophylaxis after surgical resection of primary lower extremity bone or soft‐tissue sarcoma. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27519
BibTeX
@article{LiBrizzi2024,
author = {LiBrizzi, Christa L and Agarwal, Amil R and Chiu, Anthony K and Morris, Carol D and Thakkar, Savyasachi C and Levin, Adam S},
title = {The efficacy and safety of direct oral anticoagulants compared with low‐molecular‐weight heparin for venous thromboembolism prophylaxis after surgical resection of primary lower extremity bone or soft‐tissue sarcoma},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27519}
}
EUVIMED